Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

ADC Therapeutics (ADCT) EBITDA (2019 - 2026)

ADC Therapeutics has reported EBITDA over the past 8 years, most recently at -$25.2 million for Q1 2026.

  • Quarterly results put EBITDA at -$25.2 million for Q1 2026, up 11.31% from a year ago — trailing twelve months through Mar 2026 was -$128.8 million (up 7.84% YoY), and the annual figure for FY2025 was -$141.7 million, up 10.97%.
  • EBITDA reached -$25.2 million in Q1 2026 per ADCT's latest filing, up from -$31.0 million in the prior quarter.
  • Across five years, EBITDA topped out at $4.3 billion in Q4 2022 and bottomed at -$69.4 million in Q2 2022.
  • Median EBITDA over the past 5 years was -$30.0 million (2024), compared with a mean of $651.7 million.
  • The largest annual shift saw EBITDA skyrocketed 87415.35% in 2023 before it crashed 101.31% in 2024.
  • Over 5 years, EBITDA stood at $4.3 billion in 2022, then plummeted by 37.44% to $2.7 billion in 2023, then plummeted by 101.31% to -$35.6 million in 2024, then grew by 12.92% to -$31.0 million in 2025, then grew by 18.48% to -$25.2 million in 2026.
  • Business Quant data shows EBITDA for ADCT at -$25.2 million in Q1 2026, -$31.0 million in Q3 2025, and -$44.1 million in Q2 2025.